Testosterone Enanthate in Special Populations: Transplant, HIV, and Beyond

How Testosterone Enanthate Works

Testosterone enanthate is a prodrug. The enanthate ester, a seven-carbon fatty acid chain attached to the 17-beta hydroxyl group, slows release from the intramuscular injection depot into systemic circulation. Once the ester bond is cleaved by nonspecific tissue esterases, free testosterone enters the bloodstream and binds to androgen receptors in skeletal muscle, bone, adipose tissue, and the central nervous system 3.

Inside target cells, testosterone either acts directly on androgen receptors or is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. In muscle and bone, it can also undergo aromatization to estradiol via the aromatase enzyme, contributing to bone mineral density maintenance. The half-life of testosterone enanthate is approximately 4.5 days, which supports weekly or biweekly injection schedules 4.

This pharmacokinetic profile matters for special populations. Patients with reduced muscle mass (common in HIV wasting and post-transplant cachexia) may absorb the depot differently, sometimes producing higher peak concentrations. Starting at lower doses (50 to 75 mg weekly) and titrating based on trough levels drawn 24 to 48 hours before the next injection reduces the risk of supraphysiologic spikes.

HIV-Associated Hypogonadism and Wasting

Hypogonadism affects 20% to 25% of men living with HIV, even in the era of effective antiretroviral therapy (ART), according to data from the Multicenter AIDS Cohort Study 5. The causes are multifactorial: direct viral effects on Leydig cells, chronic inflammation suppressing the hypothalamic-pituitary-gonadal axis, medication effects (particularly from older protease inhibitors and megestrol), and general illness-related suppression.

The clinical consequences are severe. Low testosterone in this population correlates with accelerated loss of lean body mass, reduced bone mineral density, depressive symptoms, and decreased quality of life. Before ART became standard, HIV wasting syndrome carried an independent mortality risk.

A randomized, placebo-controlled trial by Bhasin et al. (N=61) demonstrated that testosterone enanthate 300 mg every two weeks produced a mean 2.6 kg gain in lean body mass and a 1.7 kg reduction in fat mass over 12 weeks in men with AIDS wasting and low testosterone 2. Muscle strength, measured by leg press, improved by approximately 22%.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone replacement for HIV-positive men with confirmed low morning total testosterone (below 300 ng/dL on two separate measurements) and symptoms consistent with hypogonadism 6. The guideline does not specify a preferred ester, but testosterone enanthate is the most widely used injectable formulation in U.S. HIV clinics.

Monitoring in HIV-positive patients requires attention to drug interactions. Testosterone is metabolized by CYP3A4, and ritonavir-boosted ART regimens (such as those containing darunavir/ritonavir or atazanavir/ritonavir) can inhibit this pathway, potentially raising testosterone levels. The Infectious Diseases Society of America (IDSA) recommends checking trough testosterone levels 4 to 6 weeks after starting or changing ART in patients on concurrent TRT 7.

Hematocrit monitoring is also critical. Baseline polycythemia occurs more frequently in HIV-positive men, and testosterone therapy raises hematocrit by a mean of 3 to 5 percentage points. If hematocrit exceeds 54%, the Endocrine Society recommends dose reduction or temporary discontinuation 6.

Organ Transplant Recipients

Hypogonadism is underrecognized in solid organ transplant recipients. A cross-sectional analysis of 103 male kidney transplant recipients found that 57% had total testosterone below 300 ng/dL, with 24% falling below 200 ng/dL 8. Similar prevalence data exist for liver and heart transplant populations.

The etiology involves multiple mechanisms. Chronic kidney disease preceding transplant suppresses gonadotropin-releasing hormone pulsatility. Calcineurin inhibitors (cyclosporine, tacrolimus) directly impair Leydig cell steroidogenesis in animal models. Corticosteroids suppress luteinizing hormone secretion. Weight gain and metabolic syndrome after transplant increase aromatase activity, converting testosterone to estradiol in adipose tissue.

"Testosterone deficiency contributes significantly to post-transplant metabolic syndrome and should be actively screened for in male transplant recipients," noted Dr. Nader Pouratian, writing in the American Journal of Transplantation 9.

Safety concerns in this population center on three issues.

Polycythemia. Transplant recipients already face elevated thrombotic risk from calcineurin inhibitor-related endothelial dysfunction. Adding testosterone, which stimulates erythropoietin production, compounds this risk. Complete blood count checks every 6 to 8 weeks during the first 6 months of therapy are prudent.

Drug interactions. Testosterone and cyclosporine share CYP3A4 metabolic pathways. Case reports describe cyclosporine level fluctuations of 15% to 30% after testosterone initiation 10. Transplant pharmacists should check calcineurin inhibitor trough levels 1 to 2 weeks after any testosterone dose change.

Hepatotoxicity. Oral 17-alpha-alkylated androgens are hepatotoxic and contraindicated in liver transplant patients. Testosterone enanthate, a non-17-alpha-alkylated injectable, does not carry this risk and is preferred.

Dosing typically begins at 50 mg weekly, with titration guided by both symptom response and trough testosterone levels. The goal range is 400 to 600 ng/dL (midrange normal), avoiding the higher targets sometimes used in otherwise healthy men.

Opioid-Induced Androgen Deficiency

Chronic opioid use suppresses the hypothalamic-pituitary-gonadal axis through direct mu-opioid receptor activation in the hypothalamus. This inhibits pulsatile gonadotropin-releasing hormone secretion. A meta-analysis by Bawor et al. (N=3,862 across 17 studies) found that 69% of men on long-term opioid therapy had total testosterone below 300 ng/dL 11.

The condition, termed opioid-induced androgen deficiency (OPIAD), produces clinically meaningful effects. Patients report fatigue, decreased libido, erectile dysfunction, depressed mood, and reduced bone mineral density. These symptoms overlap with opioid side effects, making diagnosis challenging without confirmatory lab work.

The Endocrine Society recommends screening for hypogonadism in men on chronic opioids (defined as daily use exceeding 3 months) who present with sexual dysfunction, unexplained fatigue, or low bone density 6. Two morning total testosterone measurements below 300 ng/dL confirm the diagnosis.

Testosterone enanthate replacement in OPIAD follows the same principles as primary hypogonadism treatment, with one caveat: opioid dose reduction, when clinically feasible, is the first-line intervention. "Testosterone replacement should complement, not replace, efforts to taper opioid therapy when pain management allows," according to the American Association of Clinical Endocrinology (AACE) 12.

A 2019 randomized trial (N=65) by Basaria et al. found that testosterone gel (which has comparable steady-state kinetics to low-dose weekly enanthate) improved sexual function scores by 2.9 points on a validated questionnaire (P=0.004 vs. placebo) and increased lumbar spine bone mineral density by 2.1% over 12 months in men with OPIAD 13.

Aging and Frailty

The T-Trials, the largest coordinated set of randomized controlled trials of testosterone in older men, enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism. Participants received testosterone gel (titrated to maintain mid-normal levels) or placebo for 12 months 1.

Results across the seven component trials showed statistically significant improvements in sexual desire (Derogatis Inventory score increase of 0.58, P<0.001), erectile function, self-reported vitality, and 6-minute walking distance (increase of 6.0 meters vs. placebo, P=0.03). Bone mineral density and volumetric bone strength also improved in the Bone Trial component 14.

The T-Trials used testosterone gel rather than enanthate, but the pharmacodynamic endpoint is the same: sustained mid-normal serum testosterone. Weekly testosterone enanthate at 75 to 100 mg produces comparable steady-state levels in older men, with the advantage of guaranteed adherence (administered by a clinician or self-injected weekly).

Cardiovascular safety in older populations received clarification from the TRAVERSE trial (N=5,204), which followed testosterone-treated men aged 45 to 80 with cardiovascular risk factors for a mean of 33 months. The primary cardiovascular endpoint (composite of death, nonfatal MI, nonfatal stroke, or coronary revascularization) showed no significant difference between testosterone and placebo (HR 0.99 to 95% CI 0.81 to 1.21) 15.

This finding addressed a concern that had limited testosterone prescribing to older men since the 2010 Testosterone in Older Men with Mobility Limitations (TOM) trial was stopped early for excess cardiovascular events 16. The TRAVERSE data, published in the New England Journal of Medicine in 2023, provides reassurance for clinicians considering TRT in older men with documented hypogonadism and controlled cardiovascular risk factors.

Chronic Kidney Disease

Testosterone deficiency affects 40% to 60% of men with end-stage renal disease (ESRD), driven by uremic suppression of hypothalamic GnRH pulses, hyperprolactinemia from reduced renal prolactin clearance, and chronic inflammation 17.

In men on hemodialysis, testosterone enanthate at 200 mg biweekly for 6 months increased hemoglobin by 1.2 g/dL and lean body mass by 3.1 kg in a small prospective cohort (N=29), while decreasing inflammatory markers including C-reactive protein 18. The erythropoietic effect can be particularly valuable: several case series report reduced erythropoiesis-stimulating agent (ESA) dose requirements by 25% to 40% after testosterone initiation.

Post-transplant, testosterone levels may improve but frequently remain subnormal. As described in the transplant section above, immunosuppressive agents contribute to persistent hypogonadism even after graft function normalizes.

Monitoring in CKD requires measuring free testosterone (by equilibrium dialysis) rather than total testosterone, because uremia decreases sex hormone-binding globulin (SHBG) concentrations. A total testosterone in the low-normal range (e.g., 320 ng/dL) may overestimate androgenic activity. The Endocrine Society recommends free testosterone measurement when SHBG abnormalities are suspected 6.

Monitoring Protocol for Special Populations

Standard TRT monitoring applies to all patients, but special populations require additional vigilance. The following schedule reflects combined recommendations from the Endocrine Society, the American Urological Association, and population-specific guidelines.

Baseline (before starting): morning total testosterone (two measurements), free testosterone (if SHBG suspected abnormal), complete blood count, comprehensive metabolic panel, lipid panel, PSA (men over 40), and assessment for sleep apnea symptoms.

Week 4 to 6: trough testosterone level to guide dose titration, complete blood count (hematocrit check), and concomitant drug levels (cyclosporine, tacrolimus, or warfarin) if applicable.

Month 3: symptom reassessment, repeat labs (testosterone trough, CBC, PSA), and hepatic function panel in transplant recipients.

Month 6 and 12: full panel repeat. Bone mineral density (DEXA) at 12 months if baseline osteopenia or osteoporosis was present.

Annual thereafter: CBC, metabolic panel, testosterone trough, PSA, and lipid panel. DEXA every 2 years if bone health is a treatment indication.

Red flags that require immediate dose adjustment or discontinuation: hematocrit above 54%, PSA rise exceeding 1.4 ng/mL within 12 months, new or worsening sleep apnea, lower-extremity edema suggestive of heart failure exacerbation, or unexplained liver function test elevation in transplant patients.

Fertility Considerations Across Populations

Exogenous testosterone suppresses spermatogenesis by inhibiting FSH and intratesticular testosterone production. This effect is consistent regardless of the underlying condition and is relevant for any man of reproductive age in these special populations.

In HIV-positive men seeking fertility, human chorionic gonadotropin (hCG) at 1,500 to 3 to 000 IU subcutaneously two to three times weekly can maintain intratesticular testosterone while treating systemic hypogonadal symptoms 6. Selective estrogen receptor modulators (clomiphene citrate 25 to 50 mg daily) represent another option, though this use is off-label and less studied in HIV cohorts.

For transplant recipients, the decision is often simpler because immunosuppressive regimens containing mycophenolate mofetil are already teratogenic (Category D), and fertility planning requires coordinated medication changes with the transplant team regardless.

Recovery of spermatogenesis after testosterone discontinuation typically occurs within 6 to 12 months, though individual variation is wide. A meta-analysis of 30 studies found that 95% of men recovered sperm concentration above 20 million/mL within 12 months of stopping testosterone 19.